Hints and tips:
...The Department of Health and Social Care said NHS England and Novartis “continue to work closely together to roll out this treatment to those who need it”....
...Where doubts creep in is how Novartis will replace lost sales from 2027....
...The results focus on the remaining business, focused on innovative drugs, after Novartis spun out its generics division Sandoz this month....
...The crunchy acronym was coined by Goldman Sachs for pharma companies GSK and Roche, Dutch chip company ASML, Switzerland’s Nestlé and Novartis, Danish drugmaker Novo Nordisk, France’s L’Oréal and LVMH, the...
...focused Novartis”....
...Shares in Novartis were up just over 3 per cent in early trading on Tuesday, but have languished this year....
...Novartis was evaluating its legal options but had not yet filed a lawsuit, he said....
...Novartis recently said it would spin off its generic drugmaking business Sandoz....
...Results: Banco Santander FY, Boeing Q4, Chubb Q4, Fujitsu Q3, GSK Q4, H&M FY, Hitachi Q3, Mastercard Q4, Match Group Q4, Nasdaq Q4, Nomura Holdings Q3, Novartis Q4, Novo Nordisk Q4, Qualcomm Q1, Samsung...
...Founded by the Sandoz family, the business merged with Ciba-Geigy to create Novartis in 1996....
...Six years later, and Persuit, the marketplace he founded for companies to hire external lawyers, has a client list that includes US retailer Walmart and Swiss pharmaceuticals group Novartis....
...The talks between Novartis, ReiThera and the Italian government were at an early stage, the people said, and might not yield a final agreement. Novartis, ReiThera and CureVac all declined to comment....
...Susanne Schaffert, who ran the now subsumed Novartis oncology unit, and Robert Weltevreden, who led customer and technology solutions, are also leaving Novartis....
...Much depends on what Novartis does with the cash. It has its eye on acquisitions in cardiovascular diseases, immunology, neurology, hematology or oncology....
...“It’s a household name,” a top Novartis executive said of the generics business, adding that the Sandoz family retains a stake in Novartis....
...Novartis has not produced its own Covid-19 vaccine, helping instead with the manufacture of vaccines made by other pharma groups....
...“Officially the [Novartis] response will be retaining [Sandoz] is an option . . . I think it’s very unlikely.”...
...Shares in Novartis ticked 0.5 per cent higher, while Molecular Partners surged more than a third. Both companies are listed in Switzerland....
...The investment had yielded dividends of more than $6bn, Novartis said....
...In 2019 Novartis successfully spun off its Alcon eye-care division, which is now listed as a separate entity....
...News round-up Capital Group: the slow-moving giant in dangerous waters (FT) Novartis to spin off generic drugs unit Sandoz (FT) CIMC abandons $1bn deal for Maersk’s refrigerated container arm (FT) Citigroup...
...Novartis exemplified a trend for diversification. Now, the Swiss giant is shedding non-core businesses....
...Drugmakers argue the high prices — Novartis’ one-off gene therapy Zolgensma to treat spinal muscular atrophy has a US list price of $2.1mn — are good value because they save years of healthcare costs for...
...The story has been corrected to include two Novartis deals in radioligand therapy....
...Bell said the advantage of the inclisiran deal for Novartis was that it had a guaranteed market for its medicine....
International Edition